Our Doctors

Scott G. Foxman, M.D.
Founder and President
Retinal and Ophthalmic Consultants, P.C.

Retina Specialist


OFFICE LOCATIONS:

1500 Tilton Road, Northfield, NJ 08225

2466 East Chestnut Avenue, Vineland, NJ 08361

211 South Main Street, Cape May Court House, NJ 08210

PROFESSIONAL EXPERIENCE:

1986 - Present              Founder, President Retinal and Ophthalmic Consultants, P.C.

EDUCATION:

1973 - 1979                 B.A. Boston University Medical Honors Program, Boston University

1975 - 1979                 M.D. Boston University Medical Honors Program, Boston University

POSTDOCTORAL RESEARCH:

1979                            National Eye Institute

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1979 - 1980                 Intern in Medicine, Jackson Memorial Hospital, Miami

1980 - 1983                 Resident in Ophthalmology University of Minnesota, Minneapolis

1983 - 1985                 Fellowship, Vitreo-retinal Diseases Jules Stein Eye Institute, UCLA, Los Angeles

FACULTY APPOINTMENT:

1983 - 1985                 Visiting Lecturer Jules Stein Eye Institute University of California

1986 - Present             Courtesy Scheie Eye Institute University of Pennsylvania School of Medicine

1986 - 1996                 Associate Attending Ophthalmologist Division of Ophthalmology Atlantic Regional Medical Center

1997 - Present             Chief, Division of Ophthalmology Atlantic Regional Medical Center

1986 - Present             Assistant Attending Ophthalmologist Division of Ophthalmology Shore Memorial Hospital

SPECIALTY CERTIFICATION:

1979 -                          Diplomat of The National Board of Medical Examiners

1984 -                          Diplomat of The American Board of Ophthalmology

LICENSURE:             Pennsylvania, New Jersey, California

AWARDS AND HONORS:

  • NJ Top Docs 2017 and 2018
  • Marquis Who’s Who 2017
  • PROFESSIONAL SOCIETIES:

    National Societies   

    American Society of Retina Specialists
    American Academy of Ophthalmology
    American Medical Association
    Association for Research in Vision and Ophthalmology
    American Board of Ophthalmology

         
    Local Societies  

    Medical Society of New Jersey
    Medical Society of Atlantic County
    Academy of Medicine of New Jersey
    New Jersey Academy of Ophthalmology
    Retina Society of New Jersey


    CLINICAL STAFF APPOINTMENTS

    • Atlantic Regional Medical Center
    • Shore Medical Center
    • Betty Bacharach Rehabilitation Hospital
    • Scheie Eye Institute      

    ACADEMIC APPOINTMENTS

    • University of Penn
    • Courtesy Staff

    BOARD POSITIONS:

    • Past President
      Atlantic County Medical Society

    • Past President
      Lions Club Vision Care Center


    CHARITABLE POSITIONS:

    • Chairman
      Leukemia Lymphoma Regatta, 2015

    • Co-Chairman
      Leukemia Lymphoma Regatta, 2017


    • EDITORIAL POSITION:

      • Passed Business Editor
        American Society of Retina Specialists

      Research:

      Principal and/or Sub-Investigator in over 35 National Clinical Studies

      Aerpio AKB-9778-CI-5001 – Sub-Investigator
      Aerpio Therapeutics
      August 2017 – Present

      Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15MG Once Daily or
      15MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.

      Omaspect Extension Study of Spectri GX30191 – Principal Investigator
      F. Hoffman-La Roche Ltd
      March 2017 – Present

      A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety
      and Tolerability of Lampalizumab in Patients with Geographic Atrophy
      Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study.

      TOGA-01 Phase II/III – Principal Investigator
      University of Virginia Department of Ophthalmology
      February 2017 – Present

      A Randomized, Double Masked, Placebo-Controlled Study Evaluating
      ORACEA® in Subjects with Geographic Atrophy Secondary to Non-Exudative
      Age-Related Macular Degeneration.

      MAKO-OHR-1601 / Chiltern Study Code No. 35544 – Sub-Investigator
      OHR Pharmaceutical, Inc.
      June 2016 – July, 2017

      Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution,
      0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration.

      Capella R2176-3-AMD-1417 – Sub-Investigator
      Regeneron
      September 2015 – September 2016

      A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-
      Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients
      with Neovascular Age-Related Macular Degeneration.

      Spectri GX29185 – Principal Investigator
      F. Hoffman-La Roche Ltd
      August 2014 – Present

      A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study
      to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to
      Patients with Geographic Atrophy Secondary to Age-Related Macular
      Degeneration.

      SCORE2 – Sub-Investigator
      National Eye Institute, National Institutes of Health, Department of Health and
      Human Services
      March 2014-2015

      Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2):
      A Multicenter, Prospective, Randomized, Phase III Non-Inferiority Trial of Eyes
      with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing
      Intravitreal Bevacizumab Every 4 Weeks Versus Intravitreal aflibercept Every 4
      Weeks.

      ORBIT TG-MV-018 – Sub-Investigator
      ThromboGenics, Inc.
      February 2014-2015

      A Multicenter, Prospective, Observational Phase 4 Study That Will Assess
      Clinical Outcomes and Safety of Jetrea Administered in a Real-World Setting for
      the Treatment of Symptomatic Vitreomacular Adhesion (VMA) by Assessing
      Anatomical and Functional Outcomes in 1500 Patients Recruited Across
      Approximately 120 USA Retina Sites.

      Eclipse OPH1002A – Principal Investigator
      Ophthotech Corp
      September 2013 – August 2016

      A Phase III Randomized, Double-Masked, Controlled Trial to Establish the Safety
      Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three
      doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior
      Segment of the Eye.

      BAM 114341 – Sub-Investigator
      Glaxo Smith Kline
      March 2013-2015

      A Phase II Multicenter, Randomized, Double-Masked, Placebo-Controlled,
      Parallel-Group Study to Investigate the Safety, Tolerability, Efficacy,
      Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with
      Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
      (AMD)

      VGFTe-AMD-1124 – Sub-Investigator
      Regeneron
      January 2013-2014

      An Open-Label Study of the Efficacy, Safety and Tolerability of Intravitreal
      Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients
      with Neovascular Age-Related Macular Degeneration.

      PROTOCOL S – Sub-Investigator
      DRCR.net
      July 2012-Present

      Prompt Panretinal Photocoagulation versus Intravitreal Ranibizumab with
      Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy.

      Protocol V - Sub-Investigator
      DRCR.net
      July 2012-Present

      Treatment for Central Involved Diabetic Macular Edema in Eyes with Very Good
      Visual Acuity.

      VIBRANT – Sub-Investigator
      Regeneron
      June 2012-2013
      Protocol: VGFT e-RVO -1027

      A Double-Masked, Randomized, Active-Controlled Study of the Efficacy, Safety
      and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal
      Aflibercept Injection(IAI) in Patients with Macular Edema Secondary to Branch
      Retinal Vein Occlusion.

      SAKURA-Principal Investigator
      Santen Incorporated
      2011-2013
      Protocol No. 32-007:

      A Phase III, Multinational, Multi-Center, Randomized, Double-Masked Study
      Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three
      doses) for the Treatment of Active, Non-Infectious Uveitis of the Posterior
      Segment of the Eye.

      VISTA – Sub-Investigator
      Regeneron
      2011-2013
      VGFT-OD-1009

      A Double-Masked, Randomized, Active-Controlled Phase 3 Study of the Efficacy
      and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with
      Diabetic Macular Edema. PAREXEL #201601

      SHORE-Principal Investigator
      Genentech
      2011-2013
      BB-IND 8633-Protocol FVF4967g:

      BB-IND 8633-Protocol FVF4967g: A Multi-Center Randomized Study
      Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab
      Injections in Subjects with Macular Edema Following Retinal Vein Occlusion.
      April 2011-Present

      VIEW 1 EXTENTION – Sub-Investigator
      Regeneron
      2010-2012
      Protocol: VGFT-OD-0910

      Open-label, long-term, safety and tolerability extension study of intravitreal
      VEGF Trap-Eye in neovascular age-related macular degeneration.

      NAION-Principle Investigator
      Covance
      2009-Present
      Protocol: 12912

      Prospective case crossover study to assess whether PDE5 inhibitor exposure in
      men with erectile dysfunction increases the risk for the development of non-
      arteritic anterior ischemic optic neuropathy (NAION).

      COPERNICUS-Sub-Investigator
      Regeneron
      2009-April 2012
      Protocol: VGFT-OD-0819

      Randomized, Double-masked, controlled phase III study of the efficacy, safety and
      tolerability of repeated administration of VEGF Trap-Eye in subjects with
      macular edema secondary to central retinal vein occlusion (CRVO).

      HARBOR-Principle Investigator
      Genetech
      2009-2012
      Protocol: FVF4579G

      Phase III, double-masked, multi-center, randomized, active treatment, controlled
      study of the efficacy and safety of 0.5 mg and 2.0 mg Ranibizumab; administered
      monthly or on an as-needed-basis (PRN) in patients with subfoveal neovascular
      age-related macular degeneration.

      DAVINCI- Sub-investigator
      Regeneron
      2008-2010
      Protocol: VGFT-OD-0706

      A double-masked, randomized, controlled study of the safety, tolerability and
      biological effect of repeated intravitreal administration of VEGF Trap-Eye in
      patients with diabetic macular edema (DME).

      RISE - Principle Investigator
      Genentech
      2008 – 2012
      Protocol: FVF4170G

      3 year multi center study with monthly visits for patients with Diabetic Macular
      Edema comparing Lucentis with Standard of Care Laser treatments.

      CRUISE - Principle Investigator
      Genentech
      2008 – 2010
      Protocol: FVF41669

      1 year multi center study with monthly visits comparing Lucentis to sham
      procedure for patients with central retinal vein occlusion.

      HORIZON - Principal Investigator
      Genentech
      2008-2010
      Protocol: FVF3426G

      An open-label, multicenter extension study to evaluate the safety and tolerability
      of ranibizumab in subjects with choroidal neovascularization (CNV) secondary to
      age-related macular degeneration (AMD) or macular edema secondary to retinal
      vein occlusion (RVO) who have completed a Genentech-sponsored ranizumab study.

      VIEW1 - Sub-Investigator
      Regeneron
      2007 – 2010
      Protocol: VGFT-OD-0605

      Two-year multi center study with monthly visits comparing VEGF-Trap against
      Lucentis for patients with newly diagnosed age-related macular degeneration.

      SIRIUS - Sub-Investigator
      Allergan
      2006 – 2008
      Protocol: 211745-001-01

      Two-year multi center study comparing Sirna against Lucentis for age-related macular degeneration.

      NOTAL VISION HMP-V4 - Sub Investigator
      Notal Vision
      2006-2007
      Protocol: 20071801

      Sensitivity of the Home Macular Perimeter (HMP) in detection of choroidal
      neovascularization (CNV) secondary to age-related macular degeneration (ARMD).

      SAILOR - Principal Investigator
      Genentech, Inc.
      2003 – 2007
      Protocol: FVF3689G

      One-year multi center study to evaluate the safety and tolerability of Lucentis in
      newly diagnosed and previously treated subjects with age-related macular degeneration.

      Visudyne Photodynamic Therapy - Sub-Investigator
      Ciba Vision
      1999-2000

      Clinical Investigator for Visudyne Photodynamic Therapy Study.

      Flibanserin - Sub-Investigator
      University of Pennsylvania and Boehringer Ingelheim (BI Trial
      No. 1997-1998).

      Eight-week, double-blind, placebo controlled Phase II study of various doses of     
      flibanserin and paroxetine in patients with Major Depressive Disorder.  Our role was to
      perform ophthalmic examinations to evaluate for potential ocular complications and side
      effects.

      Pioglitazone - Sub- Investigator
      Takeda America, Inc.
      1996

      A double-blind placebo-controlled, randomized, dose-titration study to evaluate the
      safety and efficacy of pioglitazone, an oral hypoglycemic agent.  Our role was to perform
      retinal examinations and evaluate retinal photographs for evidence of diabetic
      retinopathy.

      Adefovir Dipivoxil (bis-POM PMEA) - Sub - Investigator
      NJCRI
      1996-1997

      A placebo-controlled study of the safety and efficacy of adefovir dipovoxil (bis-POM
      PMEA) in prolonged survival of HIV-infected individuals with a CD4+ cell count of <
      100/mm3.  Our role was for ophthalmic evaluation with emphasis on the presence or
      absence of CMV retinitis.

      Silicone Oil - Principle Investigator
      Richard James Corporation
      1993-1996

      Principal Investigator.  Clinical investigation as to the utility and safety of silicone oil
      injection in the vitreous cavity for patients with complicated retinal detachment.  Our role
      was to provide patient care including vitreoretinal surgery.

      Perfluorocarbon Liquid - Principle Investigator
      Retinal and Ophthalmic Consultants, P.C.
      1992-1996

      Clinical investigation as to the utility and safety of intra-operative use of perfluorocarbon
      liquid into the vitreous cavity during surgical reattachment of the retina.  

      Sulfur hexafluoride and Perfluoropropane - Sub - Investigator
      Retinal and Ophthalmic Consultants, P.C.
      1989-1994

      Clinical investigation as to the utility and safety of long-acting gases in the repair of
      retinal detachments.

      Diabetic Retinopathy
      National Institutes of Health
      Early Treatment of Diabetic Retinopathy Study (ETDRS)
      1984-1985

      Dr. Scott Foxman was investigator in landmark national collaborative randomized
      trial of laser treatment for diabetic retinopathy.


      Publications

      Original Papers

      • Ballantine, E., Foxman, S., Gorden, P., Roth, J.:  Rarity of Diabetic Retinopathy in Patients with Acromegaly.  Arch. Intern. Med. 1981; 141:1625-1627.

      • Foxman, S., Cameron, J.D.:  The Clinical Implications of Bilateral Microphthalmos with Cyst:  Report of a Fatal Case.  Am. J. Ophthalmol.  1984;97:632-638.

      • Foxman, S., Heckenlively, J., Bateman, J., Wirtschafter, J.:  A Classifications of Congenital and Early Onset Retinitis Pigmentosa.  Arch. Ophthalmol.  1985;103:1502-1506.

      • Foxman, S., Heckenlively, J., Sinclair, S.:  Pigmented Paravenous Retinochoroidal Atrophy and Rubeola Retinopathy. Am. J. Ophthalmol.  1985;99:605-606.

      • Fishman, M., Kerman, B., Foxman, S.:  Intraocular Cysticercus:  Migratory.  Ossonig, K. (ed):  Proceedings of the 10th SIDUO Congress, Netherlands, W. Junk, 1986.

      • Heckenlively, J., Foxman, S., Parelhoff, E.:  Retinal Dystrophy and Macular Coloboma.  Doc Ophthal.  1988:68:257-271. Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer.  Ophthalmic Surgery and Lasers.  2002:35:323-325.

      • Shields, J., Perez, N., Shields, C., Foxman, S., Foxman, B.: Simultaneous Choroidal and Brain Metastasis as Initial Manifestations of Lung Cancer. Ophthalmic Surgery and Lasers. 2002:35:323-325.

      • Foxman, S.: Finding the right fit: Considerations on both sides of the employment process.  Retina Times.  2006: 24: 25-27.

      • Foxman, S.: Office Administrator: The guide of your practice’s success.  Retina Times. 2006: 24: 47-51. 

      • Ferencz L, Lang J, Yeshurn I, Pollack A, Siegel R, Lifshitz T, Karp J et al.  Toward earlier detection of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2010 March.

      • Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY; CRUISE Investigators. Ranibizimab for macular edema following central retinal vein occlusion: six month primary end point results of phase III study.  Ophthalmology. 2010 June; 117(6):1124-1133.e1.

      Click here for additional information regarding research studies and publications by Dr. Foxman.

      back to top

     

    Our nationally recognized doctors include:

    Retina Service

    Glaucoma Service

    Cornea Service

    Oculoplastic Service

    Services Provided At:

    Each facility includes state-of-the-art equipment including:
    • » Lasers
    • » Ultrasound
    • » Optical Coherence Tomography
    • » Ophthalmic Photography
    • » Fluorescein Angiography